Chronic heart failure: a minimum for diabetologist

Czech version

Authors: Eva Gon Alvesová
Authors‘ workplace: Národný ústav srdcových a cievnych chorôb, a. s., Bratislava
Published in: Forum Diab 2020; 9(2): 98-102
Category:

Overview

Chronic heart failure is a complex clinical syndrome with a diverse and often combined aetiology. Due to the results of clinical trials with SGLT2 inhibitors showing a decrease in mortality and hospitalizations for HF in diabetic patients with high cardiovascular risk, the attention of endocrinologists is focused not only on the glycaemic control but also on the evaluation of the patient’s cardiovascular risk profile. Until now, interest in cardiovascular risk factors has focused mainly on risk of atherosclerotic vasoocclusive events. However, the results of the clinical trials suggest a high prevalence and mortality for heart failure in patients with diabetes. In this article, we provide basic information on the classification, clinical presentation, diagnosis, prognosis, and management of chronic HF. We hope the paper will be helpful for diabetologists and endocrinologists for decisions in patients referral for more detailed cardiologic evaluation, as well as for choosing the optimal pharmacotherapy for type II diabetes mellitus.

Keywords:

SGLT2 inhibitors – chronic heart failure – diabetes mellitus – diagnosis

Sources

Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016; 18(8): 891–975. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.592>.

Gonçalvesová E, Danková M, Lesný P et al. Demographic and clinical characteristics in patients hospitalised with heart failure in Slovakia. SLOVASeZ II registry. Cardiology Lett 2017; 26(5): 269–275.

Reddy YN, Carter RE, Obokata M et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction. Circulation 2018; 138(9): 861–870. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA>.

Goncalvesová E et al. Srdcové zlyhávanie. ProLitera: Bratislava 2016. ISBN 9788089668038.

Packer M. Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care 2018; 41(1): 11–13. Dostupné z DOI: <http://dx.doi.org/10.2337/dci17–0052>.

Kristensen SL, Preiss D, Jhund PS et al. [PARADIGM-HF Investigators and Committees]. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9: e002560. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002560>.

Haas SJ, Vos T, Gilbert RE et al. Are betablockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of largescale clinical trials. Am Heart J 2003; 146(5): 848–853. Dostupné z DOI: <http://dx.doi.org/10.1016/S0002–8703(03)00403–4>.

Seferović PM, Coats AJS, Ponikowski P et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail 2020; 22(2): 196–213. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1673>.

Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.

McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.